Christopher A. Marlett
Christopher Marlett is CEO and Founder of MDB Capital Group LLC. His entire 26 year career has been focused on financing emerging growth companies in the public markets.
During the last 15 years he transitioned to a core focus of financing companies that possess potentially disruptive technology. He has become a thought leader in the area of financing development stage companies in the public markets as a preferable alternative to traditional venture capital. Additionally he began studying the impact of intellectual property as a method of gaining and retaining market leadership. This led to the development of PatentVest, the first business intelligence database platform focused upon intellectual property.
He has co-founded or launched four companies into the public markets from near inception that progressed to over $1B in market value. His exclusive focus today is on financing disruptive technology. He also developed a process for creation and execution of a dominant IP position for the companies he finances as a method to gain market leadership. Mr. Marlett graduated from the University of Southern California in 1986 with a B.S. in Business Administration.
Co-founder of MDB, Mr. DiGiandomenico focuses on corporate finance and capital formation for growth-oriented companies. Prior to forming MDB Capital, he served as President and CEO of the Digian Company, a real estate development company. Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a Bachelors of Science Degree in Finance from the University of Colorado.
CFO & CCO
Mr. Schuman joined MDB Capital Group in 2009 and serves as the firm’s Chief Financial Officer and Chief Compliance Officer. Leveraging more than 18 years of securities industry experience where he has been instrumental in the launch of several investment firm start-ups, including hedge funds, broker-dealers, and investment advisors, Mr. Schuman is responsible for all financial reporting, compliance and general administration at MDB.
Previously, Mr. Schuman was the Chief Financial Officer and Chief Compliance Officer of USBX Advisory Services, LLC, an investment banking firm focused on mergers and acquisitions, and Chief Financial Officer of its parent company, USBX, Inc. Mr. Schuman also served in several managerial capacities at Equibond, Inc., a securities broker-dealer based in Los Angeles. Mr. Schuman received a Bachelor of Arts degree in Economics from UCLA and an MBA from the Marshall School of Business at the University of Southern California.
George H. Brandon
Managing Director - Business Development
Mr. Brandon has 24 years of investment experience working on both the buy and sell side. Prior to joining MDB, he served as the director of business development for Dallas, Texas based start up, MileMeter Insurance.
Mr. Brandon’s business focus has primarily been with entrepreneurial start-ups, micro-cap and small cap companies. He has served as a partner of Trinity River Advisors, LLC, a turnaround consulting firm, targeting small companies dealing with financial distress. Mr. Brandon also served as a partner for a micro-cap investment firm, Sawtooth Capital Management Inc.
His security related experiences include institutional sales of distressed securities at Drake Capital Securities and manager of the Los Angeles Office for Robert Thomas Securities, a division of Raymond James Financial. Mr. Brandon received a B.A. from Concordia University - Irvine.
Managing Director - Investment Banking
Prior to joining MDB Capital in 2010, Mr. Cotter was a Senior Managing Director of Investment Banking at Source Capital Group.
From 1998-2008 he lead the Middle Market and Private Placement group at Sanders, Morris, Harris, one of the consistently top-ranked PIPE groups on Wall Street, where he helped manage over 70 Private placement offerings with total proceeds in excess of $500 million.
In 1991, Mr. Cotter was the founding partner of Value Investing Partners, a boutique investment firm that specializes in small and micro-cap financings. Mr. Cotter has spent over 20 years building an extensive network within the U.S. hedge fund and money management community. Mr. Cotter holds a B.S. in Business Administration from Belmont Abbey College.
Robert M. Levande
Sr. Managing Director - Investment Banking
Prior to joining MDB in 2003, Mr. Levande was co-head of Life Sciences Corporate Finance at Gilford Securities and founded the Palantir Group, Inc., which specializes in providing strategic advice in business development, mergers, acquisitions, and capital raising for the medical technology industry.
From 1972 through 1999, he held numerous managerial positions of increasing responsibility with Pfizer Inc., principally in its Medical Technology Group (MTG) most recently Vice President - Business Analysis & Development of MTG. During his tenure at Pfizer, Mr. Levande actively participated in more than 20 acquisition and technology transfer agreements. He was with MTG's largest operating unit for 21 years where he helped to grow the business from sales of $50 million to over $800 million. His positions included Senior Vice President with responsibilities that included finance, planning, and business development and, previously, corporate Vice President and General Manager of the Canada, Latin America, & Far East Division.
Mr. Levande's other experience includes director of three public companies including two which he co-founded - VirnetX Inc. (now VirnetX Holding Corp.) and Pulse Biosciences, Inc., serving as Chairman of the Board of the latter from 2014 – 2017.
He holds an M.B.A. from Columbia University and a B.S. in Economics from the University of Pennsylvania's Wharton School of Finance & Commerce. Mr. Levande has also completed the Japanese Business Study Program at the Institute for International Studies and Training in Tokyo, Japan and the Spanish language program at Rennert Bilingual Institute.
Amy Wang, Ph.D.
Managing Director - Investment Banking
Dr. Amy Wang joined MDB Capital Group in 2007 to support and further our endeavors in life science and healthcare.
With an extensive scientific background as well as biotechnology industry experience, Dr. Wang seeks new transformative medical diagnostics and therapeutics. In addition to life science, Dr. Wang also has interest in biofuels and cleantechnology. Prior to joining MDB, she was a development scientist at Invitrogen, Corp.'s Biosource division where she led a team in the Signal Transduction Assay group and spearheaded development of the Epigenetics program.
Prior to Invitrogen, Dr. Wang served as a staff scientist at Amcyte, Inc., a type I diabetes cell therapy biotech (acquired by ReNeuron). She was a post-doctoral fellow at UCLA in Michael Grunstein's laboratory where she worked on chromatin modifications and gene regulation. Dr. Wang received her BS in Biochemistry and PhD from the department of Biological Chemistry at UCLA and MBA from UCLA Anderson.